Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-16673 and Sonrotoclax in Treatment-Naive CLL/SLL
NCT07508995Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2026
- Primary completion
- Jul 2031
- Modality
- Bivalent/Multivalent Binders, Orthosteric Ligands, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
A Phase 2 trial of catadegbrutinib, sonrotoclax in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by University of Texas MD Anderson Cancer Center. Started Aug 2026; status: recruiting.
02
Drugs
catadegbrutinibsonrotoclax
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT07508995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07508995.